Global Checkpoint Inhibitors Competitive Landscape Report 2023: Comprehensive Insights About 180+ Companies and 250+ Drug Profiles
08 mai 2023 06h48 HE
|
Research and Markets
Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This "Checkpoint inhibitors -...
Global Checkpoint Inhibitors Market Report 2023: Rising Number of Cancer Cases Drives Growth
24 avr. 2023 13h18 HE
|
Research and Markets
Dublin, April 24, 2023 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Immune Checkpoint Inhibitors Clinical Trial Analysis 2022: Wide Variety of Clinical and Preclinical Research Currently Ongoing Bodes Well for Growth
15 déc. 2022 05h18 HE
|
Research and Markets
Dublin, Dec. 15, 2022 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors: Analysis of Clinical Trial Results (Featuring Recently Published Trial Results, Contemporary Pipeline Review, Clinical...
Immune Checkpoint Inhibitors Global Market Report 2022: Featuring Bristol-Myers Squibb, Merck, Novartis, Pfizer & More
29 nov. 2022 08h08 HE
|
Research and Markets
Dublin, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors Market, by Drug Class, By Cancer Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity...
Worldwide Immuno-oncology Industry to 2028 - Featuring Novartis, Merck, Regeneron Pharmaceuticals and Pfizer Among Others
16 nov. 2022 04h18 HE
|
Research and Markets
Dublin, Nov. 16, 2022 (GLOBE NEWSWIRE) -- The "Immuno-oncology Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's...
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
15 nov. 2022 04h00 HE
|
AKAMPION
- Promising data presented at Protein and Antibody Engineering Summit (PEGS) - Multi-functional agent targeting three immune checkpoint receptors - Potential as mono- and combination therapy for...
Checkpoint Inhibitors for Treating Cancer Market Worth US$ 63,420.2 Million by 2031: Visiongain Reports Ltd
29 août 2022 05h00 HE
|
Visiongain Reports Ltd
Visiongain has published a new report: Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031: Forecasts by Category (PD1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, Cytokines...
Global Checkpoint Inhibitors Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F Featuring AstraZeneca, Bristol-Myers Squibb, Merck & Co, Roche, Pfizer, Incyte, Novartis, and NewLink Genetics
29 juil. 2022 06h23 HE
|
Research and Markets
Dublin, July 29, 2022 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2022: By Drug, By Application, By End-Users" report has been added to ResearchAndMarkets.com's offering. ...
The Worldwide Metastatic Cancer Drug Industry is Expected to Reach $68.3 Billion by 2028
30 juin 2022 05h33 HE
|
Research and Markets
Dublin, June 30, 2022 (GLOBE NEWSWIRE) -- The "Global Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Cancer Type, Route of Administration, Drug Class,...
Global Immune Checkpoint Inhibitors Market to 2027 - Size, Share & Industry Trends Analysis Report
26 avr. 2022 06h43 HE
|
Research and Markets
Dublin, April 26, 2022 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma,...